AlphaCentric Advisors LLC holds a diversified book of 259 stocks worth $118.0M as of Q2 2026 (disclosed Jul 24, 2026, a ~45-day 13F lag). This quarter they opened Invesco QQQ Trust Series 1 and trimmed Euronet Worldwide Inc. Their largest long position is Gilead Sciences Inc at 2% of the equity book. Cloning the disclosed picks since 2024 would be +33% (+12.2%/yr). That is a simulation of the disclosed long book, not audited returns.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1913464/holdings"
Use Arkolith to show AlphaCentric Advisors LLC's latest holdings, largest changes, and filing provenance.
Following at the filing date actually beat the quarter-end book by 13.4 points over this window.
Growth of $10,000 cloning AlphaCentric Advisors LLC's disclosed long 13F book, rebalanced on each filing date (so it reflects the ~45-day reporting lag, no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
82% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as AlphaCentric Advisors LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| BlackRock, Inc. | 79 / 80 | $134.1B |
| MORGAN STANLEY | 79 / 80 | $57.5B |
| UBS Group AG | 79 / 80 | $18.9B |
| WELLS FARGO & COMPANY/MN | 78 / 80 | $13.1B |
| FMR LLC | 77 / 80 | $53.6B |
| BANK OF AMERICA CORP /DE/ | 77 / 80 | $43.7B |
| GOLDMAN SACHS GROUP INC | 77 / 80 | $22.1B |
| ROYAL BANK OF CANADA | 77 / 80 | $12.7B |
Ranked by how many of AlphaCentric Advisors LLC's top 80 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Gilead Sciences Inc COM | $2.6M | 20.4K | 2.2% | ▲+0.8% Added · +166 sh | |
| 2 | Vertex Pharmaceuticals Inc COM | $2.5M | 5.0K | 2.1% | ▲+1.4% Added · +71 sh | |
| 3 | Invitation Homes Inc COM | $2.2M | 73.0K | 1.9% | —Held | |
| 4 | AstraZeneca PLC ORD | $2.2M | 11.4K | 1.8% | ▲+1.4% Added · +162 sh | |
| 5 | Roivant Sciences Ltd SHS | $1.7M | 48.4K | 1.4% | ▲+1.4% Added · +688 sh | |
| 6 | Argenx SE SPONSORED ADR | $1.7M | 1.8K | 1.4% | ▲+0.7% Added · +12 sh | |
| 7 | Neurocrine Biosciences Inc COM | $1.6M | 9.7K | 1.4% | ▲+1.2% Added · +120 sh | |
| 8 | Incyte Corp COM | $1.6M | 14.5K | 1.4% | ▲+1.4% Added · +206 sh | |
| 9 | Axsome Therapeutics Inc. COM | $1.6M | 6.5K | 1.4% | ▲+1.4% Added · +93 sh | |
| 10 | Apogee Therapeutics Inc COM | $1.5M | 11.5K | 1.3% | ▲+1.4% Added · +164 sh | |
| 11 | Euronet Worldwide Inc COM | $1.5M | 20.0K | 1.2% | ▼−28% Reduced · −8K sh | |
| 12 | Aeva Technologies Inc COM NEW | $1.4M | 50.0K | 1.2% | —Held | |
| 13 | Ishares TR RUS 1000 VAL ETF | $1.4M | 5.8K | 1.2% | ▼−51% Reduced · −6K sh | |
| 14 | Invesco Exchange Traded FD T S&P500 PUR VAL | $1.4M | 12.1K | 1.2% | ▼−49% Reduced · −12K sh | |
| 15 | Invesco QQQ TR UNIT SER 1 | $1.4M | 1.9K | 1.2% | ▲New New position | |
| 16 | Invesco Exch Traded FD TR II NASDAQ 100 ETF | $1.4M | 4.5K | 1.2% | ▲New New position | |
| 17 | Saul CTRS Inc COM | $1.3M | 35.0K | 1.1% | —Held | |
| 18 | Insmed Inc COM PAR $.01 | $1.2M | 11.7K | 1.1% | ▲+32% Added · +3K sh | |
| 19 | Ionis Pharmaceuticals Inc COM | $1.2M | 15.4K | 1.0% | ▼−21% Reduced · −4K sh | |
| 20 | Ascendis Pharma A/s ORD SHS | $1.2M | 4.6K | 1.0% | ▲New New position | |
| 21 | Protagonist Therapeutics Inc COM | $1.1M | 9.2K | 1.0% | ▲+1.4% Added · +131 sh | |
| 22 | Builders Firstsource Inc COM | $1.1M | 12.5K | 0.9% | ▲+25% Added · +3K sh | |
| 23 | Unusual Machs Inc COM SHS | $1.1M | 50.0K | 0.9% | ▲+43% Added · +15K sh | |
| 24 | Howard Hughes Holdings Inc COM | $1.1M | 15.0K | 0.9% | ▲New New position | |
| 25 | Ishares TR 1 3 YR TREAS BD | $1.1M | 13.0K | 0.9% | ▲+37% Added · +3K sh | |
| 26 | Personalis Inc COM | $1.1M | 78.9K | 0.9% | ▲+23% Added · +15K sh | |
| 27 | Rhythm Pharmaceuticals Inc COM | $1.0M | 9.4K | 0.9% | ▲+1.6% Added · +152 sh | |
| 28 | Stereotaxis Inc COM NEW | $1.0M | 600.0K | 0.9% | —Held | |
| 29 | Rockwell Automation Inc COM | $990K | 2.0K | 0.8% | —Held | |
| 30 | Xometry Inc CLASS A COM | $965K | 10.0K | 0.8% | ▼−20% Reduced · −3K sh | |
| 31 | Abbvie Inc COM | $909K | 3.6K | 0.8% | ▲+1.9% Added · +69 sh | |
| 32 | Jazz Pharmaceuticals PLC SHS USD | $871K | 3.6K | 0.7% | ▲+1.5% Added · +52 sh | |
| 33 | Tempus AI Inc CL A | $869K | 15.0K | 0.7% | ▲+50% Added · +5K sh | |
| 34 | Pennantpark Invt Corp COM | $868K | 250.0K | 0.7% | ▲+60% Added · +94K sh | |
| 35 | Amgen Inc COM | $855K | 2.4K | 0.7% | ▲+1.4% Added · +33 sh | |
| 36 | Biogen Inc COM | $841K | 3.9K | 0.7% | ▲+1.5% Added · +56 sh | |
| 37 | Ah Rlty TR Inc COM | $814K | 115.0K | 0.7% | —Held | |
| 38 | Smartstop Self Storag REIT I COMMON STOCK | $813K | 25.0K | 0.7% | ▼−17% Reduced · −5K sh | |
| 39 | Redwire Corporation COM | $795K | 65.0K | 0.7% | ▲+73% Added · +28K sh | |
| 40 | Globus Med Inc CL A | $790K | 10.0K | 0.7% | ▲+33% Added · +3K sh | |
| 41 | Cto Rlty Growth Inc New COM | $753K | 35.0K | 0.6% | ▼−31% Reduced · −15K sh | |
| 42 | Catalyst Pharmaceuticals Inc COM | $742K | 23.6K | 0.6% | ▲+1.4% Added · +336 sh | |
| 43 | Ondas Inc COM NEW | $742K | 90.0K | 0.6% | ▲+64% Added · +35K sh | |
| 44 | American Assets TR Inc COM | $741K | 30.0K | 0.6% | ▼−14% Reduced · −5K sh | |
| 45 | Halozyme Therapeutics Inc COM | $738K | 9.4K | 0.6% | ▲+97% Added · +5K sh | |
| 46 | Meiragtx Hldgs PLC COM | $736K | 54.5K | 0.6% | ▲+1.4% Added · +775 sh | |
| 47 | Amrep Corp COM | $733K | 29.1K | 0.6% | ▼−35% Reduced · −15K sh | |
| 48 | Krystal Biotech Inc COM | $723K | 1.9K | 0.6% | ▲+1.4% Added · +27 sh | |
| 49 | Magnum Ice Cream Co NV ORD SHS | $696K | 40.0K | 0.6% | ▲New New position | |
| 50 | Manhattan Associates Inc COM | $696K | 5.0K | 0.6% | ▲+43% Added · +2K sh |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Jul 24, 2026 | 261 | $118.0M | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 7, 2026 | 252 | $100.1M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 12, 2026 | 250 | $100.3M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Jan 31, 2025 | 212 | $100.2M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Oct 30, 2024 | 231 | $134.5M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Jul 25, 2024 | 218 | $135.8M | 13F-HR |
| Q1 2024 | Mar 31, 2024 | Apr 24, 2024 | 228 | $165.8M | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 216 | $149.0M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.